INSPIRIS RESILIA

Aortic Valve



For

Aortic valve replacement

When

Patients want the freedom of an active lifestyle with options for the future

Why

RESILIA tissue* is designed to offer enhanced[†] anticalcification technology that will potentially allow the valve to last longer

RESILIA tissue

- Significant improvement of anti-calcification properties in test valves compared to control[†]
- Sustained hemodynamic performance across 5 years¹

VFit technology[‡]

- Enables a controlled expansion during valve-in-valve deployment
- Expansion feature available on valve sizes 19–25 mm


Proven valve platform

- Built on the proven performance of the Carpentier-Edwards PERIMOUNT valve design – a valve design with published clinical durability of over 20 years²⁻⁴
- Incorporates features of the trusted PERIMOUNT valve platform to enhance ease of implant
- * No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients.
- † RESILIA tissue tested against commercially available bovine pericardial tissue from Edwards in a juvenile sheep model. Flameng, et al. J Thorac Cardiovasc Surg 2015;149:340–5.
- * Based on bench data. Refer to device **Instructions for Use** for important warnings related to VFit technology. These features have not been observed in clinical studies to establish the safety and effectiveness of the model 11500A for use in valve-invalve procedures.



Model 11500A

Size (mm)	19	21	23	25	27	29
A. Tissue Annulus Diameter (Stent Diameter, mm)	19	21	23	25	27	29
B. Internal Diameter (Stent ID, mm)	18	20	22	24	26	28
C. Profile Height (mm)	13	14	15	16	17	18
D. External Sewing Ring Diameter (mm)	25	27	29	32	34	36



Sizers/trays

1133 Sizers (one barrel/replica set per valve size, 19–29 mm)


TRAY1133



Handles

Reusable handle 1111

Single-Use handle (extended length) 1126



Scan to learn more about the product



Important Safety Information: INSPIRIS RESILIA Aortic Valve

Indications: For use in replacement of native or prosthetic aortic heart valves. Contraindications: There are no known contraindications with the use of the INSPIRIS RESILIA aortic valve. Complications and Side Effects: Thromboembolism, valve thrombosis, hemorrhage, hemolysis, regurgitation, endocarditis, structural valve deterioration, nonstructural dysfunction, stenosis, arrhythmia, transient ischemic attack/stroke, congestive heart failure, myocardial infarction, any of which could lead to reoperation, explantation, permanent disability, and death. Warnings: DO NOT ADJUST THE VALVE DIAMETER BY EXPANDING THE BAND PRIOR TO OR DURING IMPLANTATION OF THE SURGICAL VALVE. The expandable band is not designed to allow for compression or expansion during implantation of the surgical valve. This will cause damage to the valve and may result in aortic incompetence. DO NOT PERFORM STAND-ALONE BALLOON AORTIC VALVULOPLASTY PROCEDURES ON THIS VALVE FOR THE SIZES 19–25 mm as this may expand the valve causing aortic incompetence, coronary embolism or annular rupture. Valve-in-valve sizing in the INSPIRIS valve has only been tested with specific Edwards transcatheter heart valves.

Use of other transcatheter valves may result in embolization of transcatheter devices anchored within or result in annular rupture.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. See Instructions for Use for full prescribing information.

References

- 1. Bavaria JE, et al. Five-year Outcomes of Aortic Valve Replacement with a Bioprosthetic Valve with a Novel Tissue. The Society of Thoracic Surgeons, 2021 Annual Meeting.
- 2. Bourguignon T, et al. Very long-term outcomes of the Carpentier-Edwards PERIMOUNT valve in aortic position. Ann Thorac Surg. 2015;99:831 7.
- 3. Johnston DR, et al. Long-term durability of bioprosthetic aortic valves: implications from 12,569 implants. *Ann Thorac Surg.* 2015;99:1239 47.
- 4. For cillo J, et al. Carpentier-Edwards pericardial valve in the a ortic position: 25-years experience. Ann Thorac Surg. 2013; 96:486-93.
- 5. Flameng W, et al. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. *J Thorac Cardiovasc Surg.* 2015;149:340 5.

Edwards, Edwards Lifesciences, the stylized E logo, Carpentier-Edwards, Carpentier-Edwards PERIMOUNT, COMMENCE, INSPIRIS, INSPIRIS RESILIA, Magna, Magna Ease, PERI, PERIMOUNT, PERIMOUNT Magna, RESILIA, and VFit are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are property of their respective owners.

 $\hbox{@ 2021 Edwards Lifesciences Corporation.\,All rights reserved.\,PP--US-6533\,v1.0}$

